The use of the word “endotype” is recently used in respiratory medicine more frequently. In severe asthma, the biomarkers are clear in specific parts of the patients, representing around 2% of all asthma patients. In chronic obstructive pulmonary disease (COPD), the precision medicine approach is more complicated. The definition of the pathology is based on an operational test (spirometry) rather than the pathophysiological mechanisms (except for the A1AT deficiency). Moreover, different diseases like biomass-induced lung injury and cigarette smoke-induced lung injury are sharing the same treatable traits as therapeutic targets. On the other hand, recent studies identified four endotypic traits on obstructive sleep apnea (OSA) pathogenesis, raising questions about the implementation of precision medicine in this widespread disease. Other pulmonary disorders such as IPF, pneumonia, and pulmonary hypertension also have endotypes and biomarkers that could identify patient profiles to ameliorate risk of outcomes and maybe achieve better patient-related outcomes.
Accordingly, in this Research Topic we wish to extend an invitation to pulmonary researchers, focusing on the importance of identifying endotypes in the pulmonary medicine, with the final objective of highlighting new therapeutic approaches, potential prognoses and diagnoses, genetic or therapeutic biomarkers, and/or new pathophysiological mechanisms in pulmonary diseases.
Here we accept clinical trials, original research, systematic reviews, mini-reviews, and case reports addressing biomarkers in pulmonary diseases, including but not limited to the following topics:
• Therapeutic targets
• New treatments and diagnosis
• Identification of endotypes
• Discovery of novel underlying mechanisms
The use of the word “endotype” is recently used in respiratory medicine more frequently. In severe asthma, the biomarkers are clear in specific parts of the patients, representing around 2% of all asthma patients. In chronic obstructive pulmonary disease (COPD), the precision medicine approach is more complicated. The definition of the pathology is based on an operational test (spirometry) rather than the pathophysiological mechanisms (except for the A1AT deficiency). Moreover, different diseases like biomass-induced lung injury and cigarette smoke-induced lung injury are sharing the same treatable traits as therapeutic targets. On the other hand, recent studies identified four endotypic traits on obstructive sleep apnea (OSA) pathogenesis, raising questions about the implementation of precision medicine in this widespread disease. Other pulmonary disorders such as IPF, pneumonia, and pulmonary hypertension also have endotypes and biomarkers that could identify patient profiles to ameliorate risk of outcomes and maybe achieve better patient-related outcomes.
Accordingly, in this Research Topic we wish to extend an invitation to pulmonary researchers, focusing on the importance of identifying endotypes in the pulmonary medicine, with the final objective of highlighting new therapeutic approaches, potential prognoses and diagnoses, genetic or therapeutic biomarkers, and/or new pathophysiological mechanisms in pulmonary diseases.
Here we accept clinical trials, original research, systematic reviews, mini-reviews, and case reports addressing biomarkers in pulmonary diseases, including but not limited to the following topics:
• Therapeutic targets
• New treatments and diagnosis
• Identification of endotypes
• Discovery of novel underlying mechanisms
